Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Bottom Line: BM321, BM322, BM325, and BM326 showed almost completely abolished allergenic activity and induced significantly reduced T-cell proliferation and release of proinflammatory cytokines in patients' PBMCs compared with grass pollen allergens.On immunization, they induced allergen-specific IgG antibodies, which inhibited patients' IgE binding to all 4 major allergens of grass pollen, as well as allergen-induced basophil activation.A recombinant hypoallergenic grass pollen allergy vaccine (BM32) consisting of 4 recombinant PreS-fused grass pollen allergen peptides was developed for safe immunotherapy of grass pollen allergy.
Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.Show MeSH
Related in: MedlinePlus
Mentions: Next, we investigated which peptides induce allergen-specific IgG responses on immunization. Fig E3 in this article's Online Repository at www.jacionline.org shows reactivities of peptide-specific IgG antibodies with the corresponding allergens. For each of the 2 allergens, one peptide (ie, Phl p 2: P4-2; Phl p 6: P1-6) could be identified that induced levels of IgG antibodies comparable to those induced by the complete allergen (see Fig E3).
Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.